{"entity":{"id":"pipobroman","kind":"drug","name":"Pipobroman","aka":[],"tldr":"Pipobroman was an oral tablet approved in 1966 for polycythaemia vera, the blood disorder that makes too many red cells, and for chronic myeloid leukaemia; it was discontinued after studies showed it raised the risk of leukaemia compared with hydroxycarbamide.","summary":"Pipobroman controlled red cell counts in polycythaemia vera for decades, especially in France and Italy, and was approved in the United States in 1966 for polycythaemia vera and for chronic myeloid leukaemia after busulfan failure. The French Polycythemia Study Group's randomised comparison with hydroxycarbamide, followed for a median of 16 years, found more transformations to acute leukaemia and shorter survival with pipobroman, which ended its use. Hydroxycarbamide, interferon and now ruxolitinib are the cytoreductive options in polycythaemia vera.","status":"historic","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Pipobroman","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Pipobroman"},{"label":"ChEMBL CHEMBL1201205","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201205"}],"tags":["gap-fill","chembl-universe"],"related":[],"cancers":["myeloproliferative-neoplasms","cml"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["hydroxyurea","ruxolitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"brand":"Vercyte","modality":"Oral alkylating-type cytotoxic","mechanism":"A piperazine derivative with two bromopropionyl groups that acts as an alkylating agent on proliferating marrow cells; its precise mechanism was never fully defined.","approvals":[{"region":"US","year":1966,"indication":"Polycythaemia vera; chronic myeloid leukaemia refractory to busulfan (historic label)","note":"Discontinued"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pipobroman/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"hydroxyurea","kind":"drug","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}]}}